Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that is associated with many long-term adverse health and social outcomes, such as comorbid depression and anxiety, drug abuse, motor vehicle collisions and work absenteeism. Worldwide, the estimated prevalence of ADHD among children and adolescents is 5.3% to 7.1%. Although no national data on ADHD prevalence are available for Canada, prevalence was 5.5% among children aged 6 to 19 years between 2005 and 2009 in the province of Manitoba, and increased to 6.8% between 2009 and 2013. Genetic factors are important contributors to the development of ADHD, with variation in the trait being attributable to genetic differences in about 74% of cases. In addition, environmental factors such as maternal age at delivery, prenatal smoking and illicit drug use, maternal depression and prenatal exposure to antidepressant medications have also been suggested to be associated with risk of ADHD.

Recent studies have shown that people with ADHD have abnormal microbiota composition. Dysbiosis, or the perturbation of microbiota composition, in the maternal gut may disrupt the fetal gut–brain axis in utero and potentially plays a role in the occurrence of neurodevelopmental disorders. Given recent evidence of microbiota transfer in utero and antibiotic-induced fetal dysbiosis, we aimed to examine the association between prenatal antibiotic exposure and risk of ADHD.

Methods

Design, study setting and participants
We conducted a population-based retrospective cohort study of children born between 1998 and 2017 in the province of Manitoba, Canada. We extracted data from the Manitoba Population Research Data Repository, a collection of de-identified
We included all children registered in the Manitoba Health Insurance Registry who were born between Apr. 1, 1998, and Mar. 31, 2017. For each child, a minimum of 4 years of valid Manitoba health registration was required to meet the minimum age for a valid ADHD diagnosis, as recommended by the American Academy of Pediatrics. For each mother, a minimum of 2 years of health registration before the child’s birthdate was required to capture maternal baseline characteristics, such as health care use before conception and the diagnosis of mood and anxiety disorders. We followed the children from birthdate (index date) to the earliest date of diagnosis of ADHD, migration out of the province, reaching age 18 years, death or end of the study period.

We conducted the analyses for 3 cohorts. The first cohort comprised all children who met the inclusion criteria. The second cohort consisted of members of the overall cohort who were matched on high-dimensional propensity scores. To identify this cohort, we scanned all available administrative databases for predictors of the exposure and then estimated the propensity score, which is the probability of being exposed, given the values of all covariables. High-dimensional propensity scores were later used to adjust for confounding by ensuring that the 2 groups were balanced in their characteristics. The third cohort consisted of children who had at least 1 maternal sibling who did not have prenatal exposure to antibiotics.

Other data sources used in the study are described in Appendix 1 (available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.190883/-/DC1).

Exposure
We defined prenatal exposure to antibiotics as the mother having filled 1 or more outpatient antibiotic prescriptions during her pregnancy. We determined birthdate and gestational age from birth records and used these dates to estimate the date of conception. In secondary analyses, we examined the association between prenatal antibiotic exposure and risk of ADHD according to pregnancy trimester, number of antibiotic courses, cumulative duration of use and antibiotic class (Appendix 2, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.190883/-/DC1).

Outcome
The main outcome measure was a diagnosis of ADHD with hyperactivity after age 4. We used the coding systems in the clinical modification of the International Classification of Diseases, 9th Revision (ICD-9-CM), and the International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10), to identify the diagnosis of ADHD in physician outpatient claims and hospitalization records, respectively. We used the Anatomical Therapeutic Chemical drug classification system to identify drugs for treating ADHD in prescription medication dispensations. We used a standard identification algorithm, which defined diagnosis of ADHD as 1 or more hospital admissions with a diagnosis of hyperkinetic syndrome (ICD-9-CM code 314 or ICD-10 code F90), 1 or more physician visits with a diagnosis of hyperkinetic syndrome (ICD-9-CM code 314), or 2 or more prescriptions for ADHD drugs (Anatomical Therapeutic Chemical code N06BA) within a single year without a diagnosis of conduct disorder (ICD-9-CM code 312 or ICD-10 codes F63, F91, F92), disturbance of emotions (ICD-9-CM code 313 or ICD-10 codes F93, F94) or cataplexy/narcolepsy (ICD-9-CM code 347 or ICD-10 code G47.4), to avoid misidentification of cases on the basis of drug dispensations.

Covariables
We explored sociodemographic characteristics and other clinically important variables previously reported to be associated with risk of ADHD for inclusion in our analyses. We adjusted models based on the overall cohort for sex, mother’s age at delivery (categorized as < 30 yr, 30–39 yr and ≥ 40 yr), region of residence, receipt of income assistance, year of the child’s birth, birth order, mother’s medical conditions, prenatal exposure to antidepressants and frequency of physician visits in the year before conception. We included prenatal smoking, alcohol use and drug use in a sensitivity analysis of a subset of the cohort for whom these variables were available. We adjusted models based on the sibling cohort for sex, mother’s age at delivery, birth order, year of the child’s birth and prenatal exposure to antidepressants.

We estimated high-dimensional propensity scores using 5 dimensions and used these scores to match children with and without exposure to antibiotics. We identified mothers’ hospital medical diagnoses and procedures (2 dimensions), outpatient medical diagnoses and tariff codes (2 dimensions), and drug dispensations (1 dimension) during the year before the estimated conception date. We then identified the 200 most prevalent variables in each dimension and ranked them according to their frequency as once, sporadic or frequent. We selected 500 variables for inclusion in estimation of high-dimensional propensity scores, in addition to sex, region of residence, Socio-Economic Factor Index (a measure of socioeconomic status derived from census data and based on area of residence), receipt of income assistance, mother’s age at delivery, birth order, season of birth, year of the child’s birth and number of physician visits by the mother in the year before conception. We included in the regression models variables that were not sufficiently balanced between the exposure groups.

Statistical analysis
In both the overall and the sibling cohorts, we used multivariable Cox proportional hazards regression models to compare risk of ADHD between children with and without prenatal exposure to antibiotics. In the sibling cohort, we stratified the models by sibling pairs to account for correlation among siblings.

We used multivariable Cox proportional hazards regression models, stratified by matched pair, to compare risk of ADHD in the cohort matched on high-dimensional propensity scores. Children with exposure to antibiotics prenatally were matched to those without exposure in a 1-to-1 nearest-neighbour greedy match on sex, birthdate (within 365 d) and high-dimensional propensity scores within a caliper of 0.05. We examined balance across the 2 exposure groups by calculating the standardized
differences for sociodemographic characteristics, birth characteristics and relevant maternal medical conditions at baseline (Appendix 3, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.190883/-/DC1).

In the secondary analyses, we used indicator variables for each of the categories, with mutual adjustment for these variables in the models. We tested the assumption of proportional hazards by examining the correlation between various forms of follow-up time and Schoenfeld residuals of the independent variables. We also performed several sensitivity analyses, including use of stricter identification algorithms and cohort restrictions (see Appendix 4, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.190883/-/DC1). In addition, we conducted 2 negative-control analyses, examining the effect of maternal antibiotic exposure in the year before conception and the year after birth on risk of ADHD in the children. We performed these analyses to assess the risk of bias in the main analysis.

We used SAS 9.4 statistical software (SAS Institute) for all data analyses.

Ethics approval
The study was approved by the University of Manitoba Health Research Ethics Board (project no. H2016:244) and the Health Information Privacy Committee of Manitoba Health, Seniors and Active Living (HIPC no. 2016/2017–11).

Results

Study population
Of 289 449 births in Manitoba during the study period, 187 605 children met the inclusion criteria (Figure 1). In total, 70 554 (37.6%) children were exposed to antibiotics prenatally (Table 1). Among these children, 62.7% were exposed to only 1 antibiotic course, 73.9% were exposed to antibiotics for a cumulative duration of up to 2 weeks, and 50.7% were exposed to a penicillin antibiotic (Appendix 5, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.190883/-/DC1). The children were followed for a total of 1 990 452 person-years, with a median of 10.1 (interquartile range [IQR] 6.8–14.3) person-years (Table 2).

During follow-up, 16 290 (8.7%) of the children received a diagnosis of ADHD at a median age of 7.5 (IQR 6.0–9.5) years. The crude incidences for ADHD diagnosis were 10.3 cases per 1000 person-years among children with prenatal exposure to antibiotics and 6.9 cases per 1000 person-years among those without such exposure (Table 2; Appendix 6, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.190883/-/DC1).

In the second cohort, 129 674 children were matched on high-dimensional propensity scores, sex and birthdate. The baseline characteristics were well balanced between the 2 exposure groups, with standardized differences of less than 0.1 for all of the variables examined, except maternal asthma (Table 1).

Figure 1: Derivation of the overall cohort, the cohort matched on high-dimensional propensity scores and the sibling cohort.
The children were followed for a total of 1,374,484 person-years, with a median of 10.0 (IQR 6.8–14.4) person-years. During follow-up, 12,099 (9.3%) of the children received a diagnosis of ADHD. The crude incidences for ADHD diagnosis were 9.6 cases per 1000 person-years among children with prenatal exposure to antibiotics and 8.0 cases per 1000 person-years among those without such exposure (Table 2; Appendix 6).

The sibling cohort consisted of 64,019 children and 44,491 exposure-discordant pairs. The baseline characteristics of this cohort are described in Appendix 7 (available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.190883/-/DC1), and antibiotic exposure is described in Appendix 5. During total follow-up of 687,350 person-years, 6025 (9.4%) of the children received a diagnosis of ADHD (Table 3). The crude incidences for ADHD diagnosis were 9.5 cases per 1000 person-years among children with prenatal exposure to antibiotics and 8.1 cases per 1000 person-years in children among those without such exposure (Table 3; Appendix 6).

### Primary and secondary analyses

In the overall cohort, prenatal antibiotic exposure was associated with an increased risk of ADHD (hazard ratio [HR] 1.22, 95% confidence interval [CI] 1.18–1.26) (Figure 2). The highest

---

**Table 1: Baseline and birth characteristics of the overall cohort and the cohort matched on high-dimensional propensity scores (HDPS)**

| Characteristic                          | Overall cohort |  | HDPS-matched cohort |  |
|----------------------------------------|----------------|---|---------------------|---|
|                                        | Unexposed n = 117,051 | Exposed n = 70,554 | Standardized difference | Unexposed n = 64,837 | Exposed n = 64,837 | Standardized difference |
| Sex, male                              |                |                |                      |                |                |                      |
|                                       | 59,894 (51.2) | 36,172 (51.3) | 0.002                | 33,358 (51.5) | 33,358 (51.5) | 0.000                |
| Urban region of residence              |                |                |                      |                |                |                      |
|                                       | 65,305 (55.8) | 36,418 (51.6) | 0.084                | 33,417 (51.5) | 33,488 (51.7) | 0.002                |
| Socioeconomic status†                  |                |                |                      |                |                |                      |
| High                                   | 12,873 (11.0) | 5,340 (7.6)  | 0.174                | 5,995 (9.3)   | 5,223 (8.1)   | 0.066                |
| Middle                                 | 44,027 (37.6) | 23,105 (32.8) | 0.185                | 23,084 (35.6) | 22,065 (34.0) | 0.008                |
| Low middle                             | 35,291 (30.2) | 23,319 (33.1) | 0.127                | 20,448 (31.5) | 21,425 (33.0) | 0.17                 |
| Low                                    | 24,860 (21.2) | 18,790 (26.6) | 0.127                | 15,310 (23.6) | 16,124 (24.9) | 0.11                 |
| Receiving income assistance‡           | 18,503 (15.8) | 20,652 (29.3) | 0.326                | 15,681 (24.2) | 16,717 (25.8) | 0.037                |
| Maternal age at delivery, mean ± SD    | 28.7 ± 5.8     | 27.6 ± 5.9     | 0.185                | 27.8 ± 5.8     | 27.7 ± 5.9     | 0.008                |
| Breastfeeding initiation§               | 95,919 (82.3) | 54,251 (77.2) | 0.127                | 51,865 (80.4) | 50,709 (78.5) | 0.045                |
| Preterm delivery¶                      | 8139 (7.0)     | 5578 (7.9)     | 0.036                | 4694 (7.3)     | 4962 (7.7)     | 0.016                |
| Cesarean delivery                      | 23,213 (19.8) | 14,654 (20.8) | 0.023                | 12,837 (19.8) | 13,571 (20.9) | 0.028                |
| First-born child                       | 45,645 (39.0) | 24,946 (35.4) | 0.075                | 24,722 (37.4) | 23,731 (36.6) | 0.017                |
| Small for gestational age**            | 9046 (7.7)     | 5273 (7.5)     | 0.101                | 4943 (7.6)     | 4795 (7.4)     | 0.009                |
| Birth complications††                  | 11,743 (10.0) | 7150 (10.1)    | 0.003                | 6356 (9.8)     | 6623 (10.2)    | 0.014                |
| Prenatal smoking‡‡                     | 12,296 (15.4) | 11,801 (25.3) | 0.247                | 8518 (19.7)    | 10,131 (23.4) | 0.089                |
| Prenatal alcohol or drug use§§         | 8948 (11.4)    | 7117 (15.5)    | 0.121                | 5719 (13.4)    | 6270 (14.7)    | 0.037                |
| Maternal medical conditions            |                |                |                      |                |                |                      |
| Mood and anxiety disorders             | 17,082 (14.6) | 16,502 (23.4) | 0.226                | 11,930 (18.4) | 13,567 (20.9) | 0.064                |
| Asthma                                 | 5557 (4.8)     | 8399 (11.9)    | 0.261                | 4083 (6.3)     | 6854 (10.8)    | 0.154                |
| Developmental disabilities            | 1994 (1.7)     | 2029 (2.9)     | 0.078                | 1382 (2.1)     | 1689 (2.6)     | 0.031                |

Note: SD = standard deviation.

*Data are presented as number (percentage) of children, unless stated otherwise. The percentages were calculated on the basis of non-missing data.
†Based on the Socio-Economic Factor Index, a neighbourhood-level measure that is based on the Canadian census, categorized with cut points within 1 SD from the mean into high, middle, low middle and low socioeconomic status.
‡Defined as receiving income assistance for at least 2 months within 12 months before to 18 months after the index date.
§Data missing for 789 children (0.4%) in the overall cohort and 554 (0.4%) children in the matched cohort.
*Defined as gestational age less than 37 weeks. Gestational age was based on the first date of a woman's last menstrual period. Data missing for 193 children (0.1%) in the overall cohort and 133 (0.1%) children in the matched cohort.
**Defined as birth weight below the 10th percentile for gestational age and sex. Data missing for 264 children (0.1%) in the overall cohort and 186 children (0.1%) in the matched cohort.
††Includes vacuum, forceps or breech procedures (clinical modification of International Classification of Diseases, 9th Revision [ICD-9-CM] procedure codes 72, 73.3, 763.2, 652.2, 669.6; Canadian Classification of Health Interventions [CC] codes SMD53, SMD54, SMD55 and SMD56); shoulder dystocia (ICD-9-CM code 660.4); placental abruption (ICD-9-CM code 641.2); cord prolapse (ICD-9-CM code 663); uterine rupture (ICD-9-CM code 665.1) or other perinatal complications (ICD-9-CM codes 760–779).
‡‡Data missing for 61,390 children (32.7%) in the overall cohort and 43,092 children (33.2%) in the matched cohort.
§§Data missing for 63,238 children (33.7%) in the overall cohort and 44,351 children (34.2%) in the matched cohort.
risk was observed for those whose mothers filled 3 or more courses of antibiotic (HR 1.39, 95% CI 1.31–1.47) or had a duration of antibiotic therapy longer than 2 weeks (HR 1.33, 95% CI 1.27–1.39) (Table 2). The association did not change significantly in the matched cohort (HR 1.20, 95% CI 1.15–1.24), where the highest risk was observed for those whose mothers filled 3 or more courses (HR 1.22, 95% CI 1.11–1.35), had treatment duration longer than 2 weeks (HR 1.26, 95% CI 1.17–1.35) or had dispensation of a macrolide (HR 1.30, 95% CI 1.18–1.42) (Table 2). In the sibling cohort, prenatal antibiotic dispensation was not associated with increased risk of ADHD (HR 1.06, 95% CI 0.99–1.13). No significant variation in the risk was observed in the secondary analyses of the sibling cohort (Table 3).  

Sensitivity and negative-control analyses
We found no major changes in the HRs in the planned sensitivity analyses (Figure 2); however, the risk increase was less apparent when children were censored at age 6. Dispensation of antibiotics to the mother in the year before conception and the year after childbirth was associated with increased risk of ADHD in the child (HR 1.18, 95% CI 1.15–1.22, Table 2: Association between antibiotic exposure and risk of attention-deficit/hyperactivity disorder in the overall cohort and the cohort matched on HDPS

| Variable                                                | Overall cohort  |           | HDPS-matched cohort |           |
|---------------------------------------------------------|-----------------|-----------|---------------------|-----------|
|                                                         | No. of events   | Person-years* | HR† (95% CI)       | No. of events   | Person-years* | HR‡ (95% CI)       |
| Main analysis                                           |                 |           |                     |                 |           |                     |
| Prenatal antibiotic exposure                            |                 |           |                     |                 |           |                     |
| Unexposed                                               | 8649            | 1 247 467 | 1.00 (Ref.)         | 5500          | 690 186    | 1.00 (Ref.)         |
| Exposed                                                 | 7641            | 742 985   | 1.22 (1.18–1.26)    | 6599          | 684 298    | 1.20 (1.15–1.24)    |
| Secondary analyses                                      |                 |           |                     |                 |           |                     |
| Exposure by trimester§¶                                  |                 |           |                     |                 |           |                     |
| None                                                    | 8649            | 1 247 467 | 1.00 (Ref.)         | 5500          | 690 186    | 1.00 (Ref.)         |
| First                                                   | 3722            | 333 818   | 1.13 (1.09–1.17)    | 3094          | 298 488    | 1.12 (1.05–1.19)    |
| Second                                                  | 3919            | 352 091   | 1.17 (1.13–1.22)    | 3270          | 317 862    | 1.19 (1.12–1.27)    |
| Third                                                   | 3256            | 314 554   | 1.12 (1.07–1.16)    | 2752          | 286 035    | 1.07 (1.00–1.14)    |
| Antibiotic class¶                                       |                 |           |                     |                 |           |                     |
| None                                                    | 8649            | 1 247 467 | 1.00 (Ref.)         | 5500          | 690 186    | 1.00 (Ref.)         |
| Penicillin                                              | 5150            | 500 082   | 1.15 (1.12–1.19)    | 4419          | 458 112    | 1.12 (1.06–1.17)    |
| Non-penicillin β-lactam                                  | 1489            | 133 529   | 1.18 (1.12–1.25)    | 1220          | 118 134    | 1.14 (1.04–1.25)    |
| Macrolides and related antibiotics                      | 1675            | 131 987   | 1.17 (1.11–1.24)    | 1336          | 116 915    | 1.30 (1.18–1.42)    |
| Other                                                   | 2176            | 194 694   | 1.09 (1.04–1.14)    | 1806          | 174 912    | 1.08 (1.00–1.17)    |
| No. of antibiotic courses                               |                 |           |                     |                 |           |                     |
| 0                                                       | 8649            | 1 247 467 | 1.00 (Ref.)         | 5500          | 690 186    | 1.00 (Ref.)         |
| 1                                                       | 4317            | 467 362   | 1.16 (1.12–1.20)    | 3938          | 444 343    | 1.18 (1.13–1.24)    |
| 2                                                       | 1898            | 168 403   | 1.26 (1.20–1.33)    | 1623          | 153 050    | 1.22 (1.13–1.32)    |
| ≥ 3                                                     | 1426            | 107 221   | 1.39 (1.31–1.47)    | 1038          | 86 904     | 1.22 (1.11–1.35)    |
| Cumulative antibiotic duration, d                       |                 |           |                     |                 |           |                     |
| 0                                                       | 8649            | 1 247 467 | 1.00 (Ref.)         | 5500          | 690 186    | 1.00 (Ref.)         |
| 1–7                                                     | 2780            | 306 543   | 1.16 (1.11–1.21)    | 2534          | 291 069    | 1.16 (1.10–1.24)    |
| 8–14                                                    | 2412            | 241 468   | 1.20 (1.14–1.25)    | 2143          | 226 189    | 1.19 (1.11–1.27)    |
| > 14                                                    | 2449            | 194 975   | 1.33 (1.27–1.39)    | 1922          | 167 040    | 1.26 (1.17–1.35)    |

Note: CI = confidence interval, HDPS = high-dimensional propensity score, HR = hazard ratio, Ref. = reference.
*Values for person-years were rounded to the nearest integer.
†Adjusted for sex, mother’s age at delivery, region of residence, receipt of income assistance, year of child’s birth, birth order, mother’s medical conditions, prenatal exposure to antidepressants and number of physician visits by the mother in the year before pregnancy.
‡Adjusted for maternal diagnosis of asthma.
§First trimester = 0–13 weeks of pregnancy, second trimester = 14–27 weeks, third trimester = 28 weeks until date of birth.
¶A child could be exposed to antibiotics during multiple trimesters and could be exposed to multiple antibiotic classes.
and HR 1.23, 95% CI 1.19–1.27, respectively) (Figure 2). Contrary to the analysis in the overall cohort, maternal exposure to antibiotics in the year before conception and the year after childbirth was not associated with increased risk of ADHD in the sibling cohort (HR 1.04, 95% CI 0.97–1.11, and HR 0.99, 95% CI 0.92–1.06, respectively).

**Interpretation**

In our study, prenatal antibiotic exposure was not associated with increased risk of ADHD in children. Although we observed an increased risk with prenatal antibiotic exposure in the overall cohort and the matched cohort, we did not observe this association in the sibling cohort. The risk of ADHD was similar between the overall cohort and the matched cohort on high-dimensional propensity scores, sex and birthdate, which suggests that matching did not add further control for confounding beyond adjustment for the covariables in the multivariable model. The increased risk of ADHD was no longer present in the sibling cohort analysis, which would be less susceptible to unmeasured confounding by genetics and other shared factors relative to the overall and matched cohorts. This observation can be explained by the important contribution of genetics in the development of ADHD, which is partially adjusted for in the sibling-controlled analysis.

Several sensitivity analyses confirmed that the risk estimates were not sensitive to changes in exposure, outcome or covariable definitions. An association was observed in both planned

### Table 3: Association between antibiotic exposure and risk of attention-deficit/hyperactivity disorder in the sibling cohort (n = 64 019)

| Variable | No. of events | Person-years | Type of analysis; HR (95% CI) |
|----------|---------------|--------------|-------------------------------|
|         |               |              | Unadjusted | Adjusted† |
| **Main analysis** | | | | |
| Prenatal antibiotic exposure | | | | |
| Unexposed | 2913 | 360 947 | 1.00 (Ref.) | 1.00 (Ref.) |
| Exposed | 3112 | 326 402 | 1.07 (1.01–1.14) | 1.06 (0.99–1.13) |
| **Secondary analyses** | | | | |
| Exposure by trimester‡§ | | | | |
| None | 2913 | 360 947 | 1.00 (Ref.) | 1.00 (Ref.) |
| First | 1446 | 138 371 | 1.02 (0.94–1.11) | 1.03 (0.94–1.13) |
| Second | 1506 | 145 603 | 1.13 (1.04–1.23) | 1.10 (1.00–1.20) |
| Third | 1258 | 131 952 | 1.02 (0.93–1.11) | 1.02 (0.93–1.12) |
| Antibiotic class§ | | | | |
| None | 2913 | 360 947 | 1.00 (Ref.) | 1.00 (Ref.) |
| Penicillin | 2063 | 215 600 | 1.01 (0.94–1.09) | 1.03 (0.95–1.11) |
| Non-penicillin β-lactams | 582 | 55 855 | 1.18 (1.04–1.34) | 1.09 (0.96–1.25) |
| Macrolides and related antibiotics | 700 | 55 595 | 1.12 (0.99–1.26) | 1.07 (0.95–1.21) |
| Other | 784 | 77 095 | 1.01 (0.90–1.13) | 1.01 (0.89–1.13) |
| No. of antibiotic courses | | | | |
| 0 | 2913 | 360 947 | 1.00 (Ref.) | 1.00 (Ref.) |
| 1 | 1921 | 223 769 | 1.05 (0.98–1.13) | 1.04 (0.96–1.12) |
| 2 | 750 | 68 775 | 1.10 (0.98–1.28) | 1.11 (0.99–1.25) |
| ≥ 3 | 441 | 33 859 | 1.12 (0.97–1.30) | 1.10 (0.95–1.28) |
| Cumulative antibiotic duration, d | | | | |
| 0 | 2913 | 360 947 | 1.00 (Ref.) | 1.00 (Ref.) |
| 1–7 | 1233 | 146 636 | 1.06 (0.97–1.16) | 1.04 (0.95–1.15) |
| 8–14 | 1039 | 110 020 | 1.04 (0.94–1.14) | 1.03 (0.94–1.14) |
| > 14 | 840 | 69 746 | 1.14 (1.02–1.28) | 1.13 (1.01–1.27) |

Note: CI = confidence interval, HR = hazard ratio, Ref. = reference.
*Values for person-years were rounded to the nearest integer.
†Adjusted for sex, mother’s age at delivery, birth order, year of birth and prenatal exposure to antidepressants.
‡First trimester = 0–13 weeks of pregnancy, second trimester = 14–27 weeks, third trimester = 28 weeks until date of birth.
§A child could be exposed to antibiotics during multiple trimesters and could be exposed to multiple antibiotic classes.
negative controls for the overall cohort, but not for the sibling cohort, which confirms that the sibling cohort design was less susceptible to unmeasured confounding. In light of this observation, we believe that the sibling cohort captured more accurately the risk of ADHD associated with prenatal antibiotic exposure, which was not found to be significant.

Our study confirmed the findings of a previous exploratory study by Thompson and colleagues, in which numerically higher scores for symptoms of ADHD in children who received antibiotics were not statistically significant. That study was limited by small sample size and was subject to biases, given its suboptimal methodology, such as self-reported exposure data (which are susceptible to recall bias); its lack of information about antibiotic classes, number of courses and treatment duration; its use of symptoms (rather than a clinically diagnosed outcome); and the risk of confounding by genetic or environmental factors. Conversely, we were able to test the hypothesis in a larger, population-based cohort with a method that minimized the risk of confounding (through the use of high-dimensional propensity score matching and sibling-controlled analysis) and minimized the risk of misclassification of exposure and outcome (through the use of objectively ascertained measures). Future studies are warranted to examine the association of other potential dysbiosis-inducing factors and risk of ADHD, as well as the role of the microbiota in the development of ADHD at the biological and population level.

Our study had several strengths. The Manitoba Population Research Data Repository contains a large collection of data sources and provides comprehensive data on important characteristics and health system encounters for the entire Manitoba population. This allowed for a population-based study with a large sample size and a long follow-up period. Therefore, the study findings are likely generalizable to other children. In addition, we used a standard algorithm to identify ADHD from administrative databases, which eliminated any reporting bias.

Limitations
Our study also had some limitations. We adopted an algorithm for identifying ADHD that was used in previous research, but has not yet been validated. Misclassification of the outcome is therefore a

Figure 2: Hazard ratios from sensitivity and negative-control analyses in the overall cohort. Note: ADHD = attention-deficit/hyperactivity disorder, CI = confidence interval.
potential limitation. We addressed this issue by conducting a sensitivity analysis with a stricter identification algorithm and found no change in study results. Nondifferential misclassification of the clinical diagnosis of ADHD would have biased the results toward the null.

Misclassification of the exposure is another possibility, because exposure was defined on the basis of dispensation of medications, rather than actual use, and we could not account for nonadherence. The identification algorithm that we adopted defined medications for treating ADHD using the Anatomical Therapeutic Chemical code N06BA, which does not include the recently approved medication guanfacine. Therefore, some cases of ADHD could have been misclassified. The exposure definition also did not include in-hospital use. In a sensitivity analysis, we included the data available on in-hospital antibiotic dispensation, and the results remained unchanged.

Another potential limitation is unmeasured confounding by variables that were unavailable in the repository and are not shared by sibling pairs. Unmeasured confounding in the overall and matched cohorts may have overestimated the HRs. However, the sibling-controlled design likely avoided, to some extent, confounding by genetics and shared familial factors and is recommended for future studies examining the risk of ADHD.

Finally, the ADHD identification algorithm included only children with hyperactivity. Therefore, our findings may not be generalizable to children with the inattentive subtype of ADHD.

Conclusion

Prenatal antibiotic exposure was not associated with increased risk of ADHD. The association observed in some of the analyses was likely a result of confounding, as suggested by findings from the negative-control analyses and analyses of the sibling cohort. A discordant-sibling design is recommended for future studies.

References

1. Erskine HE, Ferrari AJ, Polanczyk GV, et al. The global burden of conduct disorder and attention-deficit/hyperactivity disorder in 2010. J Child Psychol Psychiatry 2014;55:328-36.
2. What is ADHD? Atlanta: Centers for Disease Control and Prevention; 2017, reviewed 2019 Aug. 26. Available: www.cdc.gov/ncbddd/adhd/facts.html (accessed 2018 July 12).
3. Langlois KA, Samokhvalov AV, Rahn J, et al. Section C. Childhood conditions. In: Health state descriptions for Canadians. Ottawa: Statistics Canada; modified 2015 Nov. 27. Available: www.statcan.gc.ca/pub/82-619-m/2012004/sections/sectionc-eng.htm (accessed 2018 May 19).
4. Jaber L, Kirsh D, Diamond G, et al. Long-term functional outcomes in Israeli adults diagnosed in childhood with attention deficit hyperactivity disorder. Isr Med Assoc J 2015;17:481-5.
5. Vingilis E, Erickson PG, Toplak ME, et al. Attention deficit hyperactivity disorder symptoms, comorbidities, substance use, and social outcomes among men and women in a Canadian sample. Biol Med Res Int 2015;2015:982072.
6. Kimino E, Imagawa H, Goto T, et al. Sociodemographics, comorbidities, healthcare utilization and work productivity in Japanese patients with adult ADHD. PLoS One 2015;10:e0132233.
7. Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metagression analysis. Am J Psychiatry 2007;164:942-8.
8. Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics 2012;9:490-2.
9. Chartier M, Brownell M, MacWilliam L, et al. The mental health of Manitoba’s children. Winnipeg: University of Manitoba, Rady Faculty of Health Sciences, Max Rady College of Medicine, Manitoba Centre for Health Policy; 2016.
Competing interests: Salaheddin Mahmud has received unrestricted research grants from Merck, GlaxoSmithKline, Sanofi Pasteur, Pfizer and Roche-Assurex for unrelated studies, and has also received fees as an advisory board member for Sanofi Pasteur. Silvia Alessi-Severini has received unrestricted research grants from Merck and Pfizer for unrelated studies. No other competing interests were declared.

This article has been peer reviewed.

Affiliations: College of Pharmacy (Hamad, Alessi-Severini, Mahmud, Kuo), Manitoba Centre for Health Policy, Department of Community Health Sciences, Max Rady College of Medicine (Alessi-Severini, Brownell), and Department of Community Health Sciences, Max Rady College of Medicine (Mahmud, Brownell), Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Man.

Contributors: All authors contributed to the study concept and design and to data interpretation. Amani Hamad conducted data formatting and analysis. Amani Hamad and I fan Kuo contributed to data acquisition and drafted the manuscript. All authors revised the manuscript for important intellectual content, approved the final version for publication and agreed to act as guarantors of the work. Amani Hamad and I fan Kuo take full responsibility for the integrity of the data and accuracy of the analysis.

Funding: This work was supported by the University of Manitoba and the Evelyn Shapiro Chair Program. Salaheddin Mahmud’s work is supported, in part, by funding from the Canada Research Chair Program.

Data sharing: We used de-identified data from the Manitoba Population Research Data Repository. The data are not publicly available but may be obtained from the data custodian, the Manitoba Centre for Health Policy (MCHP) at the University of Manitoba. Accessing the data requires submitting a formal request to MCHP and obtaining approvals from the Manitoba Health Information Privacy Committee and the Health Research Ethics Board of the University of Manitoba.

Acknowledgements: The authors thank Charles Burchill, Matt Dahl and Heather Prior, Manitoba Centre for Health Policy, for their valuable support. The authors also acknowledge the Manitoba Centre for Health Policy for allowing use of data contained in the Manitoba Population Research Data Repository under project no. H2016:244 (HIPC No. 2016/2017-11). The authors also thank Manitoba Health, Seniors and Active Living, the Winnipeg Regional Health Authority, the Manitoba Department of Families and Healthy Child Manitoba for contributing the data used in this study.

Disclaimer: The results and conclusions are those of the authors, and no official endorsement by the Manitoba Centre for Health Policy, Manitoba Health, Seniors and Active Living or other data providers is intended or should be inferred. Data used in this study are from the Manitoba Population Research Data Repository, housed at the Manitoba Centre for Health Policy, University of Manitoba, and were derived from data provided by Manitoba Health, Seniors and Active Living, the Winnipeg Regional Health Authority, the Manitoba Department of Families and Healthy Child Manitoba.

Accepted: Mar. 16, 2020

Correspondence to: I fan Kuo, ikuo@umanitoba.ca